Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax in Myeloid Malignancies
NCT04771130Phase 2Recruiting
- Sponsor
- BeOne Medicines
- Start
- May 2021
- Primary completion
- Aug 2028
- Modality
- Orthosteric Ligands
- Countries
- 10
01
Overview
A Phase 2 trial of sonrotoclax in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by BeOne Medicines. Started May 2021; status: recruiting.
02
Drugs
sonrotoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT04771130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04771130.